UNSPSC 51432203: Dihydralazine hydrochloride

This classification denotes an antihypertensive agent with the molecular formula C8H10N6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OVG1TP7A10, chemically known as 2,3-dihydrophthalazine-1,4-dione dihydrazone monohydrochloride but more generally known as dihydralazine hydrochloride, which bears US NIH Compound Identifier 198456. European Medicines Agency schedules Dihydralazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01701MIG.

Most nations, for tariff and trade purposes, schedule dihydralazine hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, DIHYDRALAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dihydralazine hydrochloride bears US NLM identifiers UMLS ID C3273349 and NCI Concept Code C97308. SMILES: C1CCC2C(C1)C(NNC2NN)NN.CL.

UNSPSC 51432203 Dihydralazine hydrochloride is a Commodity code describing a specific vasodilator pharmaceutical used in emergency and acute-care settings. State and local governments purchase this medication primarily through fire rescue departments, emergency medical services, and public health agencies as part of advanced life support drug supplies. The work solicited under this code consists of supplying pharmaceutical-grade medications that meet FDA manufacturing standards, maintain specified shelf-life requirements, and include comprehensive safety documentation. Issuing bodies include municipal purchasing departments on behalf of fire rescue operations, state health and human services commissions evaluating pharmacy benefit programs, and multistate cooperative purchasing alliances coordinating supplies across multiple jurisdictions. Recent solicitations show mixed scope: some target specific medication line items for immediate operational use, while others function as broader information-gathering exercises or framework agreements establishing pricing across multiple generic pharmaceuticals and OTC products.

Geographic activity spans at least Florida, Texas, Minnesota, and Oregon based on recent opportunities. The City of Tampa's Purchasing Department posted an IFB for Advanced Life Support Medications (26P00188) due April 8, 2026, seeking four specific medication line items including labetalol, epinephrine, adenosine, and diltiazem for Tampa Fire Rescue, with an estimated contract value of $40,000 and a Small Local Business Enterprise 5 percent bid discount available. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 to explore vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager channels, signaling state-level interest in alternative pharmaceutical supply models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802) due March 26, 2026, to establish multi-award contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract effectiveness on July 1, 2026, and award decisions weighted heavily on price competitiveness at 75 percent.